AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$INO

Inovio stock rating upgraded to buy at H.C. Wainwright on FDA approval

H.C. Wainwright upgraded Inovio Pharmaceuticals (INO) to Buy with a $5.00 price target after FDA approval of VOCERYQ, its first product. The stock trades at $0.60, near its 52-week low. Inovio expects to ship VOCERYQ in 60 days, with full deployment in Q1 2027. H.C. Wainwright estimates peak annual sales of $450 million. Inovio reported a Q2 2026 net loss of $6.0 million, narrower than expectations. Jefferies also upgraded INO to Buy with a $3.00 target.

Original reporting
investing.com
Published Nov 2, 2026, 12:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$INO
Bullish
high confidence
Mentioned
$INO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INOBullishHigh
01

Why it matters

The approval unlocks commercial launch, supports a price target increase, and may lift the stock from its low‑price range.

02

Market read

Regulatory approval combined with an analyst upgrade creates a clear short‑term trading catalyst.

03

What to watch

Potential reimbursement challenges and competition from mRNA therapies.

Relevance 8/10Novelty 9/10Timing: today

Background

Inovio (NASDAQ:INO) announced FDA accelerated approval of its lead product VOCERYQ for recurrent respiratory papillomatosis.

Company-level read

Ticker impact

$INOBullishHigh confidence
Context

Inovio received FDA accelerated approval for VOCERYQ, its first DNA‑medicine product, prompting an upgrade to Buy.

Expected impact

likely upward pressure as the market prices in the approval and higher price target

Evidence & confidence

The approval is a primary regulatory event for a micro‑cap biotech and the upgrade adds a concrete catalyst.

Market effects

Sector

May boost sentiment for DNA‑medicine and biotech sector peers.

Regional

Limited to US biotech market.

Global

Modest; primarily US investors.

Counterpoint

What could challenge this read

The approval could be delayed by post‑marketing requirements, limiting near‑term upside.

Key entities

  • company
    Inovio Pharmaceuticals

    Biotech firm receiving FDA approval.

  • analyst
    H.C. Wainwright

    Upgraded Inovio to Buy with a $5 target.

Read at source← All news

StoryInovio receives FDA accelerated approval for VOCERYQ, its first commercial product

Also covered by

5 outlets

Related articles

NOV 2
$INOHighAI 9/10

Inovio shares surge 229% as FDA approves first commercial product

Inovio Pharmaceuticals' shares rose 229% after the FDA approved VOCERYQ, its first commercial product. The treatment targets a rare respiratory disease, with 27% of patients in a study requiring no surgeries post-treatment. Inovio estimates 25,000 U.S. adults have the disease and plans to start shipping in about 60 days, with full deployment in Q1 2027. The pricing is expected to be $460,000 for the full regimen.

finance.yahoo.com2 min
NOV 2
$INOHighAI 8/10

There's Always A Bull Market Somewhere

Inovio Pharmaceuticals (INO) surged 200% after-hours following FDA approval of its treatment, Voceryq. The stock had dropped 22% during regular trading. Biotech sector gains were driven by FDA innovations and AI-assisted drug discovery. Other biotech stocks like Genmab (GMAB), Prime Medicine (PRME), Replimune (REPL), and Glaukos (GKOS) also saw significant gains. The article highlights potential investment opportunities in biotech with upcoming regulatory milestones.

zerohedge.com2 min
NOV 2
$INOMedAI 9/10

FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP

The FDA approved Inovio's Voceryq, a plasmid DNA-based immunotherapy, for treating recurrent respiratory papillomatosis (RRP) in adults. The treatment aims to reduce surgical interventions. The approval was based on a study showing 27% of patients required no surgery after 12 months. Inovio must conduct post-approval trials to confirm clinical benefits. According to the company, the treatment targets HPV-infected cells, offering a new option for RRP patients.

ajmc.com7 min
NOV 2
$INOMedAI 9/10

INOVIO Receives FDA Accelerated Approval for VOCERYQ to Reduce Surgery Frequency in Adults with RRP

INOVIO (INO) received FDA accelerated approval for VOCERYQ, a DNA-based immunotherapy for recurrent respiratory papillomatosis (RRP). The approval is based on Phase 1/2 trial results showing 27% of patients had no surgery needed for 12 months. VOCERYQ is expected to launch commercially in Q1 2027, with continued approval contingent on confirmatory study results.

finance.yahoo.com5 min